...
首页> 外文期刊>Clinical and experimental allergy : >Lung effects of inhaled corticosteroids in a rhesus monkey model of childhood asthma
【24h】

Lung effects of inhaled corticosteroids in a rhesus monkey model of childhood asthma

机译:吸入糖皮质激素对儿童哮喘恒河猴模型的肺部影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: The risks for infants and young children receiving inhaled corticosteroid (ICS) therapy are largely unknown. Recent clinical studies indicate that ICS therapy in pre-school children with symptoms of asthma result in decreased symptoms without influencing the clinical disease course, but potentially affect postnatal growth and development. The current study employs a primate experimental model to identify the risks posed by ICS therapy. Objective: To (1) establish whether ICS therapy in developing primate lungs reverses pulmonary pathobiology associated with allergic airway disease (AAD) and (2) define the impact of ICS on postnatal lung growth and development in primates. Methods: Infant rhesus monkeys were exposed, from 1 through 6 months, to filtered air (FA) with house dust mite allergen and ozone using a protocol that produces AAD (AAD monkeys), or to FA alone (Control monkeys). From three through 6 months, the monkeys were treated daily with ICS (budesonide) or saline. Results: Several AAD manifestations (airflow restrictions, lavage eosinophilia, basement membrane zone thickening, epithelial mucin composition) were reduced with ICS treatment, without adverse effects on body growth or adrenal function; however, airway branching abnormalities and intraepithelial innervation were not reduced. In addition, several indicators of postnatal lung growth and differentiation: vital capacity, inspiratory capacity, compliance, non-parenchymal lung volume and alveolarization, were increased in both AAD and Control monkeys that received ICS treatment. Conclusions and Clinical Relevance: Incomplete prevention of pathobiological changes in the airways and disruption of postnatal growth and differentiation of airways and lung parenchyma in response to ICS pose risks for developing primate lungs. These responses also represent two mechanisms that could compromise ICS therapy's ability to alter clinical disease course in young children.
机译:背景:婴幼儿接受吸入糖皮质激素(ICS)治疗的风险很大程度上未知。最近的临床研究表明,ICS疗法在患有哮喘症状的学龄前儿童中导致症状减轻,但不影响临床疾病进程,但可能影响出生后的生长发育。当前的研究采用灵长类动物实验模型来确定ICS治疗带来的风险。目的:(1)确定ICS治疗灵长类动物肺部是否能逆转与变应性气道疾病(AAD)相关的肺病理学;(2)确定ICS对灵长类动物产后肺生长和发育的影响。方法:使用产生AAD的方案,将婴儿恒河猴暴露于室内尘螨过敏原和臭氧的过滤空气(FA)中1到6个月,或单独暴露于FA(对照猴子)。从三到六个月,每天用ICS(布地奈德)或生理盐水治疗猴子。结果:ICS治疗降低了几种AAD表现(气流受限,灌洗嗜酸性粒细胞增多,基底膜区增厚,上皮粘蛋白成分),而对人体生长或肾上腺功能无不利影响;然而,气道分支异常和上皮内神经支配并未减少。此外,接受ICS治疗的AAD和对照猴子均增加了出生后肺生长和分化的几个指标:肺活量,吸气能力,顺应性,非实质肺体积和肺泡化。结论和临床意义:对ICS的反应未能完全预防气道的病理生物学变化以及产后生长的中断以及气道和肺实质的分化会引发灵长类肺的发展。这些反应还代表了两种机制,可能会影响ICS治疗改变幼儿临床疾病进程的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号